ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

bilastine

Also written as “Bilastine”, “Bilastine oral dispersible tablets” and “Bilaxten oral dispersible tablets”.

Its studies are mostly in Rhinitis, Allergic, Seasonal · Conjunctivitis, Allergic · Urticaria · Rhinitis, Allergic · Asthma, led by 4 companies.

Drug pageBilastine: every studyAll 22 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jan 9, 200719 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Faes Farma140 open or runningphase 3since Jan 9, 2007Jan 8, 2007none ahead
Menarini Groupits history only30 open or runningphase 4since Oct 13, 2015Oct 13, 2015none ahead
Humanis Saglık Anonim Sirketiits history only10 open or runningphase 1since Jun 20, 2025Jun 20, 2025none ahead
Yuhanits history only10 open or runningphase 3since Jul 20, 2011Jul 20, 2011none ahead

Also a collaborator on its studies: ORA, Dynamic Science S.L., Allied Research International and Merck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Faes Farma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 8, 2007First study: phase 2 study in Rhinitis, Allergic, SeasonalFirst studyNCT00420082 · 75 enrolled · Austria
  2. Jan 8, 2007Phase 1 study in Rhinitis, AllergicNCT00419783 · 30 enrolled · United States
  3. Jan 9, 2007Phase 3 study in UrticariaNCT00421109 · 522 enrolled · Argentina, Belgium, France and more
  4. Jul 19, 2007Phase 3 study in Rhinitis, Allergic, SeasonalNCT00504933 · 683 enrolled
  5. Dec 12, 2007Phase 1 study in HealthyNCT00572611 · 6 enrolled · United Kingdom
  6. Dec 14, 20072 phase 2 studies in Rhinitis, Allergic, SeasonalNCT00574379, NCT00574210
  7. Mar 4, 2010Phase 2 study in Chronic UrticariaNCT01081574 · 36 enrolled · Australia, Germany, Sweden
  8. Apr 21, 2010Phase 3 study in Rhinitis, Allergic, SeasonalNCT01108783 · 720 enrolled
  9. May 13, 2010Phase 1 study in HealthyNCT01124123 · 12 enrolled · Spain
  10. May 19, 2010Phase 3 study in Rhinitis, Allergic, PerennialNCT01127620 · 650 enrolled
  11. Jul 20, 2017Phase 2 study in Conjunctivitis, AllergicNCT03231969 · 121 enrolled · United States
  12. Mar 21, 2018Phase 3 study in Conjunctivitis, AllergicNCT03479307 · 228 enrolled · United States
  13. Mar 1, 2021Phase 3 study in Conjunctivitis, AllergicNCT04810390 · 59 enrolled · Spain

TargetBeta

HRH1 →read by rule
“Histamine H1 receptor inverse agonist”ChEMBL 37, by rule

Other programs on HRH1

ProgramCompanyFurthest phaseStudies
desloratadineruleOrganonphase 440
fexofenadineruleSanofiphase 438
DiphenhydramineruleJohnson & Johnsonphase 416

Studies

All 14 Faes Farma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04810390Conjunctivitis, Allergic · Spain3CompletedNov 30, 202259
NCT03479307Conjunctivitis, Allergic · United States3CompletedAug 9, 2018228
NCT03231969Conjunctivitis, Allergic · United States2CompletedOct 11, 2017121
NCT01127620Rhinitis, Allergic, Perennial3CompletedMar 2006650
NCT01124123Healthy · Spain1CompletedJun 201012
NCT01108783Rhinitis, Allergic, Seasonal3CompletedAug 2003720
NCT01081574Chronic Urticaria · Australia, Germany, Sweden2CompletedJun 201236
NCT00574379Rhinitis, Allergic, Seasonal · United States2CompletedMar 2008805
NCT00574210Rhinitis, Allergic, Seasonal · Canada2CompletedFeb 2008502
NCT00572611Healthy · United Kingdom1CompletedDec 20076
NCT00504933Rhinitis, Allergic, Seasonal3CompletedNov 2005683
NCT00421109Urticaria · Argentina, Belgium, France and more3CompletedJul 2007522
NCT00420082Rhinitis, Allergic, Seasonal · Austria2Completed75
NCT00419783Rhinitis, Allergic · United States1CompletedDec 200630

How it is read

Names in the registry

  • “Bilastine”, 13 entries
  • “bilastine”, 2 entries
  • “Bilastine oral dispersible tablets”, 1 entry
  • “Bilaxten oral dispersible tablets”, 1 entry
  • “Bilastine 0.2%”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.